Published in final edited form as:

Chem Sci. 2012 January 1; 3(1): 77–83. doi:10.1039/C1SC00336D.

Clickable, photoreactive inhibitors to probe the active site microenvironment of fatty acid amide hydrolase†

Susanna M. Saario, Michele K. McKinney, Anna E. Speers, Chu Wang, and Benjamin F. Cravatt

The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA, 92037; Fax: +858-784-8223; Tel: +858-784-8633

Benjamin F. Cravatt: cravatt@scripps.edu

Abstract

Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that degrades the endocannabinoid anandamide (AEA) and several other bioactive lipid amides. The catalytic mechanism of FAAH has been largely elucidated, and structural models of the enzyme suggest that it may recruit its hydrophobic substrates directly from the lipid bilayer of the cell. Testing this hypothesis, however, requires new tools to explore FAAH–substrate interactions in native cell membranes. Here, we have addressed this problem by creating clickable, photoreactive inhibitors that probe the microenvironment surrounding the FAAH active site. We show that these probes can be used directly in cell membranes, where distinct crosslinked adducts are observed for inhibitors that are buried within *versus* exposed to the external environment of the FAAH active site.

1. Introduction

Fatty acid amides are a large class of signalling lipids that regulate a diverse array of physiological processes in mammals.^{1,2} Representative fatty acid amides include the endogenous cannabinoid (endocannabinoid) anandamide,³ the feeding-related lipid N-oleoyl ethanolamine,⁴ and the sleep-inducing substance oleamide.⁵ Although multiple biosynthetic pathways exist for fatty acid amides,⁶ these lipids are degraded principally by a single enzyme—fatty acid amide hydrolase (FAAH).^{7–10} Genetic¹¹ or pharmacologic^{12–14} inactivation of FAAH leads to elevated brain levels of many fatty acid amides, including anandamide, and produces cannabinoid receptor-dependent reductions in pain without the cognitive or locomotor defects caused by direct receptor agonists like tetrahydrocannabinol, the psychoactive component of marijuana. These findings have led to the development of several classes of FAAH inhibitors as potential therapeutic agents for treating pain and other neurological disorders.^{12,13,15–18}

FAAH is an integral membrane enzyme that appears to interact with the lipid bilayer of cells through two distinct mechanisms: 1) an N-terminal transmembrane domain, and 2) a hydrophobic patch that monotonically inserts into the membrane.¹⁹ Structural studies have revealed that the hydrophobic patch of FAAH is positioned just above the enzyme's active site, and, in certain FAAH–inhibitor structures, a continuous tunnel is observed that connects the buried catalytic triad (Ser241–Ser217–Lys142) to the membrane-interacting

†Electronic supplementary information (ESI) available: Detailed synthesis and characterization of probes **5a–d**, LC-MS analysis (extracted chromatograms) of crosslinked and noncrosslinked peptides, and LC-MS/MS analysis (SEQUEST) of crosslinked and noncrosslinked peptides. See DOI: 10.1039/c1sc00336d

Correspondence to: Benjamin F. Cravatt, cravatt@scripps.edu.

surface of the enzyme.²⁰ We have hypothesized that this structural adaptation may allow FAAH to directly access and recruit its hydrophobic lipid amide substrates from cell membranes into the enzyme's active site.

The aforementioned hypothesis has, however, remained untested due to a lack of tools and methods for interrogating the microenvironment surrounding the FAAH active site. For such an approach to succeed, it would ideally enable the characterization of FAAH in native membrane preparations. Here, we have addressed this problem by creating clickable, photoreactive inhibitors of FAAH. We show that these probes can be used directly in cell membranes, and find that inhibitors of varying length produce distinct crosslinked adducts depending on whether they are buried within or exposed to the external environment surrounding the FAAH active site.

2. Experimental procedures

2.1 Generation of FAAH and TAP(CBP/FLAG)-FAAH constructs

Mouse FAAH in the pcDNA vector was generated as described previously.⁷ The coding sequence for the calmodulin binding peptide and FLAG tags were synthesized (Integrated DNA Technologies) and cloned at the N-terminus of FAAH in the pcDNA3 vector giving TAP(CBP/FLAG)-FAAH.

2.2 Recombinant expression of FAAH and TAP(CBP/FLAG)-FAAH proteins in COS-7 cells and cell membrane preparation

Briefly, COS-7 cells were grown to ~70% confluency in 10 cm dishes in complete medium (DMEM with L-glutamine, nonessential amino acids, sodium pyruvate, and FCS) at 37 °C and 5% CO₂. The cells were transiently transfected using pcDNA3 encoding mouse FAAH or TAP(CBP/FLAG)-FAAH using the FUGENE 6 (Roche Applied Science) transfection reagent according to the manufacturer's protocols. After two days, cells were washed twice with phosphate-buffered saline (PBS; pH 7.4), collected by scraping, re-suspended in 1.0 mL PBS, and pelleted by centrifugation at 5000 rpm for 5 min at 4 °C. The resulting supernatant was discarded and the cells re-suspended in PBS and lysed by sonication. The lysed cells were centrifuged at 100,000 × g for 45 min at 4 °C, the supernatant was discarded and the pellet was re-suspended in PBS by sonication. Protein concentrations were measured by using the Bio-Rad DC Protein Assay Kit, and aliquots were stored at –80 °C until use.

2.3 *In vitro* inhibition potency studies

Inhibitor analysis was carried out as described previously.^{21,22} Briefly, cell membranes (1 mg mL⁻¹ in PBS, pH 8, 50 µl) were pre-incubated with varying concentrations of probe (1 µl of 50×stock in DMSO added to provide 0.002–20 µM final concentration) for 10 min at RT. ¹⁴C-Oleamide (1.25 µl, 4 mM stock in DMSO, 100 µM final concentration) was added, incubated for 5 min, and the reaction quenched with 400 µl of 0.5 M HCl. The solution was then extracted with 600 µl of ethyl acetate. The organic layer was removed and dried under a stream of gaseous N₂, solubilized in 10 µl of ethyl acetate, and separated by TLC (60% ethyl acetate in hexanes). The radioactive compounds were quantified using a Cyclone Phosphorimager (PerkinElmer Life Sciences).

2.4 Competitive ABPP and click-chemistry studies

Competitive ABPP and click-chemistry reactions were performed as previously described.²² Briefly, cell membranes (100 µg of protein in 50 µl of PBS) were incubated with 2 µM probe (1 µl of 100 µM DMSO stock) for 1 h at RT, followed by 5 µM rhodamine-tagged fluorophosphonate^{23,24} (FP-Rh; 1 µl of 250 µM stock in DMSO) for 1 h at RT. For click-

chemistry reaction, membranes were first treated with 2 μ M probe followed by click chemistry reaction with 25 μ M rhodamine-azide (RhN₃, 1 μ l of 1.25 mM DMSO stock). Reactions were quenched with an equal volume (50 μ l) of 2 $\times$ SDS loading buffer, separated by SDS-PAGE, and visualized by in-gel fluorescence scanning with a Hitachi FMBio Iie flatbed fluorescence scanner (MiraiBio).

2.5 Crosslinking studies

Cell membranes (400 μ g of protein in 200 μ l of PBS) were incubated with 2 μ M probe (4 μ l of a 100 μ M DMSO stock) for 1 h at RT with or without PF-3845 (2 μ M) pre-treatment (1 h at RT). Reaction mixtures were treated either with or without UV irradiation (365 nm) for 1 h, followed by click chemistry reaction with 25 μ M RhN₃ as described above. Proteins were precipitated as follows: four volume of methanol and one volume of chloroform were added, samples were vortex-mixed and three volume of water was added. After vortex-mixing and centrifugation at 14,000 rpm ($\sim 9000 \times g$) for 3 min, the top and bottom layers were removed leaving behind the protein interface. The protein pellet was re-suspended in 500 μ l of methanol by sonication and pelleted by centrifugation at 14,000 rpm for 3 min. Methanol was removed, 50 μ l of 25 mM ammonium bicarbonate/6M urea (aq.) was added and samples were heated at 65 $^{\circ}$ C for 5 min. After denaturation, proteins were treated with 10 mM DTT (0.5 μ l of 1 M DTT in water) for 15 min at 65 $^{\circ}$ C to reduce disulfides. Cysteines were alkylated by incubating samples with 30 mM iodoacetamide (3 μ l of 0.5 M iodoacetamide in water) for 30 min in dark at RT. The urea concentration of samples was diluted to 2 M with 25 mM ammonium bicarbonate and samples were treated with or without trypsin (16 μ g ml⁻¹) or endoproteinase Lys-C (3 μ g ml⁻¹) for 3 h at 37 $^{\circ}$ C. After digestion, samples were diluted with 2 $\times$ Tricine SDS sample buffer, run on Novex® 10–20% Tricine Gel 1.0 mm (Invitrogen) and visualized by in-gel fluorescence scanning with a Hitachi FMBio Iie flatbed fluorescence scanner (MiraiBio).

2.6 Mass spectrometry studies

2.6.1 Sample preparation—Membranes (1 mg protein in 200 μ l of PBS) from COS-7 cells transiently transfected with TAP(CBP/FLAG)-FAAH were incubated with 10 μ M probe (2 μ l of 1 mM DMSO stock) for 1 h at RT. Reaction mixtures were treated either with or without UV irradiation (365 nm) for 10 min. Immunoprecipitation was performed as follows: 200 μ l of ANTI-FLAG M2 affinity gel beads were washed three times with 4 ml of TBS (50 mM Tris HCl, pH 7.4, 150 mM NaCl) by centrifugation (30 s at $2800 \times g$) in a 15 ml conical tube. The probe treated membranes were diluted to 2 ml with lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% TRITON X-100), added to washed gel beads and rotated for 3 h at 4 $^{\circ}$ C. The gel beads were centrifuged for 30 s at $2800 \times g$, supernatant was discarded and beads were washed three times with 1 ml of lysis buffer. The beads were transferred to a micro Bio-Spin column and washed five times with 500 μ l of PBS and five times with 500 μ l of milli-Q water by centrifugation (mini-fuge). Trypsin digestion on-beads was performed as follows: The premixed solution of 250 μ l of 2 M urea in PBS, 2.5 μ l of 100 mM CaCl₂ in water, 5 μ l of sequence-grade modified trypsin (20 μ g reconstituted in 40 ml of the Trypsin buffer) was added to the beads and samples were incubated for 3 h at 37 $^{\circ}$ C with agitation. The beads and supernatants were transferred to a Bio-Spin column and supernatant was eluted into a low adhesion tube by centrifugation. The beads were washed once with 100 μ l of water and the wash was combined with the elution. 17 μ l of formic acid was added and samples were stored at -80° C until mass spectrometric analysis.

2.6.2 Liquid chromatography-tandem mass spectrometry—Digested peptide mixtures were pressure-loaded on a fused silica microcapillary loading column (250 micron i.d., 360 micron o.d.) packed with 2 cm of reversed-phase resin (Aqua C18, 5 micron, 125

A, Phenomenex) fitted with a fritted microfilter (Upchurch). Following loading, the sample was washed with Buffer A (95% milliQ water/5% acetonitrile/0.1% formic acid) for ~5 min. The loading column was then attached in-line to a microcapillary column (100micron i.d., 360micron o.d., with in-house pulled 5 micron tip) packed with 10 cm Aqua C18 reversed phase resin. The sample was analyzed by heated (60 °C) liquid chromatography-tandem mass spectrometry (LC-MS/MS) using an in-house fabricated column heater as described.²⁵ The LC-MS/MS instrumentation consisted of an Agilent 1100-series quaternary pump (with manual flow-split system delivering a flow rate of 0.5 uL/min through the microcapillary tip) and Velos LTQ-Orbitrap mass spectrometer running Xcalibur Software (Thermo-Scientific) outfitted with an in-house fabricated nano-electro-spray platform. Peptides were eluted by an increasing gradient of Buffer B (95% acetonitrile/5% MilliQ water/0.1% formic acid; Gradient: 20min Buffer A; 0–45% Buffer B over 60 min; 45–100% Buffer B over 10 min; 100% Buffer B 10 min) and data were collected in data-dependent acquisition mode with dynamic exclusion enabled (repeat count of 1, exclusion duration of 60 s). One full MS1 scan (400–1800 *m/z*) was followed by 7 data dependent MS2 scans of the most abundant ions. All other parameters were left at default values.

2.6.3 MS1 spectra analysis—Masses corresponding to the unmodified and probe-modified FAAH active site peptides were manually extracted from each MS1 chromatogram using a 50 ppm mass tolerance window in QualBrowser (Thermo-Scientific). The observed mass reported is the monoisotopic mass averaged over the entire peak. Extracted peaks were also cross-correlated with the scan number of Sequest assignments for modified and unmodified peptides to confirm identity. For ratio calculation of modified peptide before and after crosslinking, the area under the curve (AUC) for each modified active site peptide was first normalized to the AUC for the unmodified active site peptide to control for variation between runs (see Supplemental Table S1†).

2.6.4 MS2 spectra analysis—The MS2 spectra data were extracted from the raw file using RAW Xtractor (version 1.9.9.1; publicly available at <http://fields.scripps.edu/?q=content/download>). MS2 spectra data were searched using the SEQUEST algorithm²⁶ (Version 3.0) against the latest version of the human IPI database concatenated with the reversed database for assessment of false-discovery rates.²⁷ SEQUEST searches allowed for differential probe modification on serine (5a: +473.232; 5b: +515.279; 5c: 572.300; 5d: 614.347), static modification of cysteine (+57.021 due to alkylation), and no enzyme specificity. The resulting MS2 spectra matches were assembled into protein identifications and filtered using DTASelect²⁸ (version 2.0.47) using the following filter criteria: –trypstat –mass –modstat –y 2; –trypstat applies different statistical models for the analysis of tryptic, half-tryptic, non-tryptic peptides; –mass uses delta mass for statistics; –modstat uses separate models for modified peptides; –y 2 restricts to fully tryptic peptides. DTASelect 2.0 uses a quadratic discriminant analysis to achieve a user-defined maximum peptide false positive rate; the default parameters (maximum false positive rate of 5%) was used for the search; however, the actual false positive rate was lower (0.5–1%) for all searches. Results are summarized in Supporting Information Table S1.†

†Electronic supplementary information (ESI) available: Detailed synthesis and characterization of probes **5a–d**, LC-MS analysis (extracted chromatograms) of crosslinked and noncrosslinked peptides, and LC-MS/MS analysis (SEQUEST) of crosslinked and noncrosslinked peptides. See DOI: 10.1039/c1sc00336d

3. Results and discussion

3.1 Chemical probe design and synthesis

Building on the success of activity-based probes that contain electrophilic and/or photoreactive groups for enzyme labeling,²⁹ we sought to incorporate four elements into our active site probes for FAAH: a carbamate electrophile (1) for covalent labeling of the enzyme's catalytic serine nucleophile²² connected through a variable-length linker (2) to a benzophenone photo-crosslinker^{30,31} (3) and a clickable alkyne group^{30,31} (4) (Fig. 1). Once covalently bonded to the FAAH serine nucleophile, probe-enzyme adducts would be exposed to UV light to induce crosslinking to proximal molecular species. Click chemistry to suitable reporter tags (fluorophore, biotin) could then be used to visualize, enrich, and characterize the crosslinked products.^{32,33} By comparing the structures of these crosslinked adducts for probes of varying length, the environment surrounding the FAAH active site could be systematically explored. Toward this end, we synthesized four clickable, photoreactive inhibitors (Fig. 1) with increasing linker lengths between the carbamate and benzophenone groups (see Supporting Information for synthesis†). Briefly, 4,4'-diaminobenzophenone was reacted with a Boc-protected amino fatty acid (**1a–d**, Scheme S1†) and the resulting compound was coupled with 5-hexynoic acid using DCC/DMAP (HOBt). After Boc-deprotection using TFA, the amino group was reacted with phenyl chloroformate to give the final compound (**5a–d**).

3.2 FAAH inhibition

Compounds **5a–d** were all found to inhibit FAAH with good potency as determined by a radiolabeled substrate assay,³⁴ showing IC_{50} values between 200–750 nM (Fig. 2a). For use in complex proteomes, the probes also needed to show selectivity for FAAH relative to other serine hydrolases, which have the potential to react with carbamates. Competitive activity-based protein profiling (ABPP)³⁵ was used to assess the specificity of compounds **5a–d** for FAAH. Membrane proteomes from COS-7 cells transfected with FAAH were treated with **5a–d** and then reacted with fluorophosphonate-rhodamine (FP-Rh),²⁴ which serves as a general ABPP probe for serine hydrolases.³⁶ Compounds **5a–d** completely and selectively blocked FP-Rh labeling of FAAH at 2 μ M when compared to mock and DMSO treated membranes (Fig. 2b, left). To further confirm the selectivity of **5a–d** for FAAH, **5a–d**-treated cell membranes were reacted with rhodamine-azide (RhN₃) under click chemistry conditions.^{32,33} FAAH was observed to be the primary target of **5a–d** in COS-7 cell membranes (Fig. 2b, right).

3.3 Gel-based crosslinking studies

Having confirmed that **5a–d** were potent and selective FAAH inhibitors, we next investigated their photocrosslinking profiles in COS-7 cell membranes expressing FAAH (Fig. 3). In this assay, membrane proteomes from FAAH-transfected cells were treated with **5a–d** and exposed to long-wave UV light to induce crosslinking. Probes were conjugated to RhN₃ under click chemistry reaction conditions, and proteomes were either directly analyzed by SDS-PAGE and in-gel fluorescence scanning or first precipitated with methanol/chloroform to remove lipids and excess click reagents and then treated with trypsin (Fig. 3, lanes 5–8, all panels) or endoproteinase Lys-C (Fig. 3, lanes 9–12, all panels) prior to SDS-PAGE analysis (using 10–20% Tricine gels). As observed previously (Fig. 2b), a 65 kDa band representing FAAH was observed in non-digested samples (Fig. 3, lanes 3–4, all panels). In the photocrosslinked samples (Fig. 3, lane 4, all panels), FAAH appeared to migrate at a slightly higher molecular weight with an intensity largely unaffected by crosslinking, suggesting that reaction occurred in an intramolecular fashion (to FAAH itself) or in an intermolecular manner to a small molecule (< ~2 kDa). We also observed a probe-reactive 75 kDa protein in undigested, crosslinked samples, but this band

was not inhibited by PF-3845 (see, for example, Fig. 3 lanes 2 and 4) so we believe that it reflects a non-specific target of the probes.

In noncrosslinked trypsin-digested samples (Fig. 3, lane 7, all panels; see also Fig. 4a, lane 3, all top panels), a single probe-labeled band was observed at ~3.7 kDa, which corresponds to the predicted mass of FAAH's active site tryptic peptide modified with **5a–d** and the Rh tag (theoretical masses: 3.66–3.80 kDa for **5a–d**). In the photocrosslinked, trypsin-digested samples, the active-site peptide band migrated as one or more higher molecular weight bands (Fig. 3, lane 8, all panels; see also Fig. 4a, lane 4, all top panels). For **5b–d**, the uncrosslinked ~3.7 kDa peptide appears to be largely absent in the photocrosslinked samples (Fig. 3, lane 8, panels **5b–d**; see also Fig. 4a, lane 4, top panels **5b–d**); in contrast, for **5a**, this uncrosslinked peptide was still observed in photocrosslinked samples (Fig. 3, lane 8, panel **5a**; see also Fig. 4a, lane 4, top panel **5a**), indicating incomplete crosslinking for the shortest probe. A much higher molecular weight crosslinked product was also observed specifically for **5a**, but not the other probes (see Fig. 4b for direction comparison). This may represent an internal crosslinking event within the FAAH protein that links two tryptic peptides together, as has been observed in previous photocrosslinking studies aimed at mapping the FAAH active site.³⁷ Consistent with this premise, modeling suggests that probe **5a** is the only probe within the **5a–5d** series that would place the benzophenone group within the active site of FAAH (Fig. 5).

Similar trends were observed for Lys–C digested samples. In noncrosslinked samples (Fig. 3, lane 11, all panels; see also Fig. 4a, lane 3, bottom panels), the dominant band was observed to migrate at ~5 kDa, which corresponds to the predicted mass of the **5a–d**-modified/Rh-conjugated FAAH active site peptide (theoretical masses: 5.01–5.15 kDa for **5a–d**). In the crosslinked, Lys–C-digested samples for **5b–d** (Fig. 3, lane 12, panels **5b–5d**; see also Fig. 4a, lane 4, bottom panels), the dominant band is shifted to higher MW with concurrent disappearance of the uncrosslinked peptide band. The shortest probe, **5a**, was again observed to behave differently than its counterparts with longer linkers; a light band corresponding to the uncrosslinked peptide was the only significant band in the UV-treated sample (Fig. 3, lane 12, panel **5a** versus **5b–5d**; see also Fig. 4a, lane 4, bottom panel **5a** versus **5b–5d**). Importantly, none of the putative probe-labeled FAAH protein/peptide bands were present in samples pre-treated with the selective FAAH inhibitor PF-3845¹³ (Fig. 3, lanes 1–2, 5–6, 9–10, all panels; see also Fig. 4a, lanes 1–2, all panels), confirming that they originate from active site-labeling of FAAH rather than cross reactivity with another cellular protein.

Taken together, these data indicate that the longer active-site probes **5b–d** produce a similar photocrosslinking profile that differs substantially from the profile generated with the shorter active-site probe **5a**. These data are consistent with modelling studies indicating that probes **5b–d** project the benzophenone crosslinker out of the FAAH active site, possibly into the cell membrane, while the benzophenone group of shortest probe **5a** is predicted to remain within the FAAH active site (note that probe **5a** is ~7 angstroms shorter than probe **5b** and this is about the same distance between the benzophenone carbonyl of **5a** and the surface of the enzyme active site that is predicted to interface with the membrane). That a similar mass shift is observed for the products of **5b–d** when FAAH is digested with either trypsin or Lys–C suggests that the crosslinked biomolecule may be non-proteinaceous in nature.

3.4 Mass spectrometry-based crosslinking studies

We next used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to characterize the probe-labeled active site peptides before and after crosslinking. COS-7 cell

membranes expressing a FLAG epitope-tagged FAAH were incubated with probes **5a–d** and then treated with or without UV irradiation to effect crosslinking. FAAH proteins were enriched by anti-FLAG antibody beads and trypsin digested on the solid support. The released peptides were then analysed by LC-MS/MS. Quantification of the integrated peak of the probe-labeled active site FAAH peptide revealed a dramatic decrease in its abundance after photocrosslinking as shown in Fig. 6 for probe **5a** (see Supplemental Figure S1 for complete analysis of all probes†). Due to the length and hydrophobicity of the probe-labeled peptides, they were observed to elute at the very end of the chromatographic gradient (95–100% Buffer B), even with LC conducted at 60 °C. The elution profile was not altered by varying the gradient or using larger pore size reversed-phase resins (data not shown). Because any crosslinked products would be larger and likely even more hydrophobic than the non-crosslinked species we were not surprised that these crosslinked adducts were unobservable using our sample analysis conditions; indeed, a thorough search for modified peaks by comparative LC analysis and MS extraction of theoretical products failed to identify crosslinked species (data not shown). Future analysis of crosslinked products will involve use of alternate digestion strategies to reduce the length (and thus retention time) of the labeled active site peptide and resultant crosslinked products, as well as other possible modifications to the chromatography procedure to facilitate characterization of very large and hydrophobic modified peptides.

Conclusions

Understanding how enzymes interact with their physiologic substrates in native cellular environments is an important problem. This is especially pertinent for integral membrane enzymes, which often perform chemistry on hydrophobic substrates (*e.g.*, lipids, other transmembrane proteins) that are themselves embedded within the lipid bilayer. It seems likely that, in these instances, enzymes would have evolved an intricate mechanism for interacting with the cell membrane to access their substrates and release products. Nonetheless, there are few methods to probe enzyme–membrane interactions in complex biological systems. Here, we have presented a chemoproteomic strategy that addresses this problem for the integral membrane enzyme FAAH. We generated a set of covalent FAAH inhibitors that also possess photocrosslinking and clickable groups and used these reagents to probe the microenvironment outside of the FAAH active site. By varying the length of the probes, we generated data that support selective intermolecular crosslinking to a small-molecular weight product(s) for the longer probes that are modelled to protrude from the FAAH active site. While we do not yet know the identity of this crosslinked product, it may represent a lipid constituent of the membrane. Future studies will attempt to address this question, but will likely require extensive optimization of protease-digestion and LC-MS protocols to generate a crosslinked product that can be detected and characterized.

The method described herein should be applicable to many other enzymes, especially those for which covalent inhibitors are available. Indeed, Overkleeft and colleagues recently reported an investigation of proteasomal subunit interactions using photoreactive, clickable inhibitors.³⁸ Our studies thus extend this active-site crosslinking approach to a membrane enzyme and show that it is amenable to complex proteomic environments from transfected cells. Conceivably, the method could also be applied to membrane preparations from tissues that naturally express FAAH (*e.g.*, brain, liver), since the active site probes can be fully functionalized to enable labeling, photocrosslinking, and coordinated detection and affinity enrichment (by clicking to ‘trifunctional’ biotin/fluorophore azide tags³²) of enzymes. The continued advancement of chemoproteomic methods for characterizing active site interactions should greatly enrich our understanding of how enzymes function in native biological environments.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Institutes of Health Grant DA017259 (B.F.C), Academy of Finland Grant 130650, University of Kuopio (S.M.S), and the Skaggs Institute for Chemical Biology.

Notes and references

1. Di Marzo V, Bisogno T, De Petrocellis L. *Chem Biol.* 2007; 14:741–756. [PubMed: 17656311]
2. Fowler CJ, Holt S, Nilsson O, Jonsson KO, Tiger G, Jacobsson SO. *Pharmacol, Biochem Behav.* 2005; 81:248–262. [PubMed: 15935456]
3. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. *Science.* 1992; 258:1946–1949. [PubMed: 1470919]
4. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo-Rodriguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D. *Nature.* 2001; 414:209–212. [PubMed: 11700558]
5. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. *Science.* 1995; 268:1506–1509. [PubMed: 7770779]
6. Simon GM, Cravatt BF. *Mol BioSyst.* 2010; 6:1411–1418. [PubMed: 20393650]
7. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. *Nature.* 1996; 384:83–87. [PubMed: 8900284]
8. Ahn K, McKinney MK, Cravatt BF. *Chem Rev.* 2008; 108:1687–1707. [PubMed: 18429637]
9. Deutsch DG, Ueda N, Yamamoto S. *Prostaglandins, Leukotrienes Essent Fatty Acids.* 2002; 66:201–210.
10. Fowler CJ, Jonsson KO, Tiger G. *Biochem Pharmacol.* 2001; 62:517–526. [PubMed: 11585048]
11. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. *Proc Natl Acad Sci U S A.* 2001; 98:9371–9376. [PubMed: 11470906]
12. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D. *Nat Med.* 2003; 9:76–81. [PubMed: 12461523]
13. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF. *Chem Biol.* 2009; 16:411–420. [PubMed: 19389627]
14. Holt S, Comelli F, Costa B, Fowler CJ. *Br J Pharmacol.* 2005; 146:467–476. [PubMed: 16100529]
15. Lichtman AH, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D, Cravatt BF. *J Pharmacol Exp Ther.* 2004; 311:441–448. [PubMed: 15229230]
16. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF. *Proc Natl Acad Sci U S A.* 2000; 97:5044–5049. [PubMed: 10805767]
17. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, Cravatt BF. *Biochemistry.* 2007; 46:13019–13030. [PubMed: 17949010]
18. Koutek B, Prestwich GD, Howlett AC, Chin SA, Salehani D, Akhavan N, Deutsch DG. *J Biol Chem.* 1994; 269:22937–22940. [PubMed: 8083191]
19. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. *Science.* 2002; 298:1793–1796. [PubMed: 12459591]
20. Mileni M, Johnson DS, Wang Z, Everdeen DS, Liimatta M, Pabst B, Bhattacharya K, Nugent RA, Kamtekar S, Cravatt BF, Ahn K, Stevens RC. *Proc Natl Acad Sci U S A.* 2008; 105:12820–12824. [PubMed: 18753625]
21. Alexander JP, Cravatt BF. *J Am Chem Soc.* 2006; 128:9699–9704. [PubMed: 16866524]
22. Alexander JP, Cravatt BF. *Chem Biol.* 2005; 12:1179–1187. [PubMed: 16298297]

23. Jessani N, Liu Y, Humphrey M, Cravatt BF. *Proc Natl Acad Sci U S A*. 2002; 99:10335–10340. [PubMed: 12149457]
24. Patricelli MP, Giang DK, Stamp LM, Burbaum JJ. *Proteomics*. 2001; 1:1067–1071. [PubMed: 11990500]
25. Speers AE, Blackler AR, Wu CC. *Anal Chem*. 2007; 79:4613–4620. [PubMed: 17500534]
26. Eng J, McCormack AL, Yates JR. *J Am Soc Mass Spectrom*. 1994; 5:976–989.
27. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. *Anal Chem*. 2002; 74:5383–5392. [PubMed: 12403597]
28. Tabb DL, McDonald WH, Yates JR. *J Proteome Res*. 2002; 1:21–26. [PubMed: 12643522]
29. Cravatt BF, Wright AT, Kozarich JW. *Annu Rev Biochem*. 2008; 77:383–414. [PubMed: 18366325]
30. Sieber SA, Niessen S, Hoover HS, Cravatt BF. *Nat Chem Biol*. 2006; 2:274–281. [PubMed: 16565715]
31. Salisbury CM, Cravatt BF. *Proc Natl Acad Sci U S A*. 2007; 104:1171–1176. [PubMed: 17227860]
32. Speers AE, Cravatt BF. *Chem Biol*. 2004; 11:535–546. [PubMed: 15123248]
33. Speers AE, Adam GC, Cravatt BF. *J Am Chem Soc*. 2003; 125:4686–4687. [PubMed: 12696868]
34. McKinney MK, Cravatt BF. *J Biol Chem*. 2003; 278:37393–37399. [PubMed: 12734197]
35. Leung D, Hardouin C, Boger DL, Cravatt BF. *Nat Biotechnol*. 2003; 21:687–691. [PubMed: 12740587]
36. Bachovchin DA, Ji T, Li W, Simon GM, Blankman JL, Adibekian A, Hoover H, Niessen S, Cravatt BF. *Proc Natl Acad Sci U S A*. 2010; 107:20941–20946. [PubMed: 21084632]
37. Patricelli MP, Cravatt BF. *Biochemistry*. 2001; 40:6107–6115. [PubMed: 11352748]
38. Geurink PP, Florea BI, Van der Marel GA, Kessler BM, Overkleeft HS. *Chem Commun*. 2010; 46:9052–9054.

Fig. 1.
Schematic for crosslinking studies with probes **5a–d**.

Fig. 2.

Potency and selectivity of probes **5a–d** as inhibitors of FAAH. a) Concentration-dependent inhibitor curves for probes **5a–d**. Varying concentrations of **5a–d** were pre-incubated with cell membranes for 10 min. ¹⁴C-Oleamide was added, reaction was quenched in 0.5 M HCl at 5 min, and the solution was extracted with ethyl acetate. The organic layer was removed, dried, re-solubilized, and separated by TLC. The radioactive compounds were quantified using a Cyclone Phosphorimager. The data represent the mean $\pm$ SEM of an experiment conducted in duplicate. IC_{50} values were calculated using nonlinear regression sigmoidal dose-response-variable slope. b) Competitive ABPP with FP-Rh and click-chemistry with RhN₃. COS-7 cell membranes were treated with **5a–d** (2 μ M), followed by FP-Rh (left lanes) or click chemistry reaction with RhN₃ (right lanes). Reactions were quenched with 2 $\times$ SDS loading buffer, separated by SDS-PAGE, and visualized by in-gel fluorescence scanning (top; image shown in grey-scale) or Western blotting (bottom) with anti-FAAH rabbit polyclonal antibodies. Western blot confirms equal loading of FAAH for both experiments.

Fig. 3.

Tricine gels of crosslinked and noncrosslinked samples treated with or without trypsin or Lys-C protease. Briefly, FAAH-transfected COS-7 cell membranes were incubated with 2 μ M **5a–d**. As a control, membranes pre-treated with the FAAH inhibitor PF-3845 (2 μ M) are shown for comparison (lanes 1–2, 5–6, and 9–10, all panels). Reaction mixtures were treated with or without (alternating lanes) UV irradiation (365 nm) and subjected to click chemistry with RhN₃. For digested samples, proteins were precipitated with methanol/chloroform prior to reduction, alkylation, and digestion with either trypsin (lanes 5–8, all panels) or Lys-C (lanes 9–12, all panels). Samples were separated on 10–20% Tricine gels and visualized by in-gel fluorescence scanning (fluorescent images shown in grey scale). See Fig. 4 for enlarged views of trypsin- and Lys-C-digested bands in the 2–25 kDa range.

Fig. 4.

Tricine gels of crosslinked and noncrosslinked samples. **a)** Enlarged images of trypsin-digested (top) and Lys-C-digested (bottom) samples from Fig. 3, 2–25 kDa range. Briefly, FAAH-transfected COS-7 cell membranes were incubated with 2 μ M probe **5a–d**. As a control, membranes pre-treated with the FAAH inhibitor PF-3845 (2 μ M) are shown for comparison (lanes 1–2, all panels). Reaction mixtures were treated with or without (alternating lanes) UV irradiation (365 nm) and subjected to click chemistry with RhN₃. For digested samples, proteins were precipitated with methanol/chloroform prior to reduction, alkylation, and digestion with either trypsin (top) or Lys-C (bottom). Samples were separated on 10–20% Tricine gels and visualized by in-gel fluorescence scanning (fluorescent images shown in grey scale). **b)** Tricine gel of noncrosslinked and crosslinked trypsin-digested samples for **5a–d** run side-by-side. Sample preparation and analysis same as for **a**, above.

Fig. 5.

Probes **5a–d** docked into the three-dimensional structure of rat FAAH. Crystal structure of humanized-rat FAAH conjugated with ligand OL135 (PDB: 2WJ2) was used as starting template to manually build FAAH-probe docking models using PyMOL. Initial three-dimensional structures of Probes **5a–d** were generated by ChemDraw 12.0. The first alkyl linker connecting the carbamate group in Probes **5a–d** was structurally aligned with the alkyl linker of the OL1 ligand in the crystal structure, which enables the head (carbamate) of each probe to be docked in the ligand binding channel of native rat FAAH. Dihedral angles of carbon–carbon bonds within the first and second alkyl linker regions were then adjusted in preferred rotameric states to release steric clash between the tail (benzophenone) of the probe and the protein.

Fig. 6.

LC-MS analysis showing loss of probe-modified FAAH active site peptide following crosslinking for probe **5a**. Extracted ion chromatograms correspond to the probe-labeled active site FAAH peptide before (black) and after (red) photocrosslinking. Relative peak area after crosslinking is indicated in parenthesis. The probe-modified residue is catalytic Ser241. See Supplemental Figure S1 for LC-MS analysis of all probes. Note: peak identities and site-of-labeling (Ser241) were confirmed by SEQUEST²⁶ analysis of tandem mass spectra as summarized in Supplemental Table S1.